Want to see CVKD full AI Analyst Report?
Cadrenal Therapeutics, Inc. (CVKD) AI Stock Analysis
Top Page
Cadrenal Therapeutics, Inc.
(NASDAQ:CVKD)
The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn) and bearish technical trends (below major moving averages with negative MACD). Corporate events provide a meaningful offset due to regulatory progress and strategic review/partnership positioning, while valuation remains limited by loss-making status and no dividend.
Cadrenal Therapeutics, Inc. (CVKD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 468.59K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.96
- Revenue Growth
- ―
- EPS Growth
- 44.80%
- Country
- US
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cadrenal Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This tre...
Cadrenal Therapeutics, Inc. Financial Statement Overview
Summary
Financials reflect an early-stage, pre-revenue biotech with widening losses and persistent cash burn (TTM operating/free cash flow about -$10.2M). The main offset is a low-leverage balance sheet with effectively no debt and improved equity versus 2022, but the company remains dependent on external financing until revenue emerges.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -956 | 0 | -1,880 | 0 | -1,266 |
| EBITDA | -11.56M | -13.23M | -10.65M | -8.34M | -6.61M |
| Net Income | -11.54M | -13.24M | -10.65M | -8.36M | -6.71M |
Balance Sheet | |||||
| Total Assets | 5.59M | 4.33M | 10.12M | 8.52M | 778.17K |
| Cash, Cash Equivalents and Short-Term Investments | 2.39M | 4.01M | 10.02M | 8.40M | 32.59K |
| Total Debt | 0 | 0 | 0 | 21.35K | 640.71K |
| Total Liabilities | 1.50M | 1.59M | 2.68M | 826.88K | 6.33M |
| Stockholders Equity | 4.09M | 2.74M | 7.44M | 7.69M | -5.55M |
Cash Flow | |||||
| Free Cash Flow | -10.16M | -12.60M | -7.36M | -3.53M | -1.32M |
| Operating Cash Flow | -10.16M | -12.60M | -7.36M | -3.53M | -1.31M |
| Investing Cash Flow | -412 | -5,104 | -6,537 | -3,254 | -2,486 |
| Financing Cash Flow | 6.98M | 6.60M | 8.98M | 11.90M | 1.35M |
Cadrenal Therapeutics, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Neutral. The current price of 0.98 is above the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.14, and below the 200-day MA of 3.94, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.72 is Neutral, neither overbought nor oversold. The STOCH value of 39.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVKD.
Cadrenal Therapeutics, Inc. Risk Analysis
Cadrenal Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Cadrenal Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCadrenal Therapeutics, Inc. Peers Comparison
Overall Rating
- CVKD46Neutral
CLGN43Neutral
DARE42Neutral
HIND40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CVKD | 46Neutral | $3.51M | -0.20 | -406.38% | ― | ― | 44.80% |
| CLGN | 43Neutral | $7.82M | -0.44 | -215.58% | ― | -86.76% | 16.63% |
| DARE | 42Neutral | $13.76M | -0.89 | -748.08% | ― | ― | ― |
| HIND | 40Underperform | $12.63M | -0.06 | -254.62% | ― | -97.99% | 99.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CVKD | Cadrenal Therapeutics, Inc. | 0.98 | -12.51 | -92.70% | |
| DARE | Daré Bioscience | 0.70 | -1.22 | -63.59% | |
| HIND | Vyome Holdings, Inc. | 1.80 | -4.51 | -71.47% | |
| CLGN | CollPlant Biotechnologies Ltd. | 4.13 | -18.66 | -81.86% | |
| LNAI | Lunai Bioworks, Inc. | 0.16 | -6.80 | -97.65% | |
| TAOX | Tao Synergies Inc. | 2.83 | -5.10 | -64.31% |
Cadrenal Therapeutics, Inc. Corporate Events
Cadrenal Therapeutics Begins Strategic Review of Orphan Portfolio
PositiveOn October 7, 2026, Cadrenal Therapeutics said its board had launched a formal strategic review to maximize the value of the company and its portfolio of orphan thrombo-inflammatory therapeutics, retaining Tungsten Advisors as exclusive financial adv...
Cadrenal Shareholders Approve Equity Plan and Board Changes
PositiveAt its Annual Meeting of Stockholders on September 24, 2026, Cadrenal Therapeutics, Inc. secured shareholder approval to amend its 2022 Successor Equity Incentive Plan, lifting the total number of shares available for awards to 1,000,000. The change...
Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway
PositiveOn August 31, 2026, Cadrenal Therapeutics reported positive feedback from a July 28, 2026 FDA Type D meeting that clarified the regulatory path for its Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia. The FDA and the comp...
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy
PositiveCadrenal Therapeutics, Inc., a late-stage biopharmaceutical player in critical care cardiology and orphan cardiovascular diseases, has built a portfolio around CAD-1005 for heparin-induced thrombocytopenia, frunexian for cardiac surgery anticoagulati...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026